GC
TEVA icon

Globeflex Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Globeflex Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-32,893
Closed -$1.06M – 462
2017
Q1 		$1.06M Buy
+32,893
New +$1.12M 0.25% 161

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Globeflex Capital's TEVA Position: Q2 2017 in Review

Globeflex Capital sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 32,893 shares — an estimated $1.06M sold.

Globeflex Capital first reported a position in TEVA in Q1 2017 and held it in 1 quarter. The position peaked at $1.06M in Q1 2017. 648 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

  • Globeflex Capital reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Globeflex Capital sold 32,893 Teva Pharmaceuticals shares in Q2 2017, an estimated $1.06M.
  • Globeflex Capital first reported a position in Teva Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Globeflex Capital's Teva Pharmaceuticals position peaked at $1.06M in Q1 2017.
  • 648 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Globeflex Capital's 13F filing for Q2 2017, filed 11 Aug 2017.